Interleukin-6 deficiency accelerates cisplatin-induced acute renal failure but not systemic injury

Toxicology

Volumn 265, Issue 3, 2009, Pages 115-121

  Mitazaki, S ^a   Kato, N ^b   Suto, M ^b   Hiraiwa, K ^b   Abe, S ^a  

^a TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; IL 6 deficiency; Renal failure

Indexed keywords

CISPLATIN; INTERLEUKIN 6; NITROGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SUPPRESSOR OF CYTOKINE SIGNALING 2; UREA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION; KIDNEY CELL; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TOXICOKINETICS; UREA NITROGEN BLOOD LEVEL; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOOD UREA NITROGEN; CISPLATIN; GENE EXPRESSION PROFILING; HEME OXYGENASE-1; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; KIDNEY FAILURE, ACUTE; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-FOS; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 71749085031     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.10.005     Document Type: Article

References (37)

1. Arany I., Megyesi J.K., Kaneto H., Price P.M., and Safirstein R.L. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol. Renal Physiol. 287 3 (2004) F543-F549
2. Auernhammer C.J., Isele N.B., Kopp F.B., Spoettl G., Cengic N., Weber M.M., Senaldi G., and Engelhardt D. Novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) stimulates corticotroph function via a signal transducer and activator of transcription-dependent mechanism negatively regulated by suppressor of cytokine signaling-3. Endocrinology 144 4 (2003) 1202-1210
3. Bauer S., Rasika S., Han J., Mauduit C., Raccurt M., Morel G., Jourdn F., Benahmed M., Moyse E., and Patterson P.H. Leukemia inhibitory factor is a key signal for injury-induced neurogenesis in the adult mouse olfactory epithelium. J. Neurosci. 23 5 (2003) 1792-1803
4. Duan L., Aoyagi M., Tamaki M., Yoshino Y., Morimoto T., Wakimoto H., Nagasaka Y., Hirakawa K., Ohno K., and Yamamoto K. Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor alpha. Clin. Cancer Res. 10 1 Pt 1 (2004) 234-243
5. Ezure T., Sakamoto T., Tsuji H., Lunz III J.G., Murase N., Fung J.J., and Demetris A.J. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am. J. Pathol. 156 5 (2000) 1627-1639
6. Faubel S., Lewis E.C., Reznikov L., Ljubanovic D., Hoke T.S., Somerset H., Oh D.J., Lu L., Klein C.L., Dinarello C.A., and Edelstein C.L. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 322 1 (2007) 8-15
7. Fram R.J. Cisplatin and platinum analogues: recent advances. Curr. Opin. Oncol. 4 6 (1992) 1073-1079
8. Greten F.R., Weber C.K., Greten T.F., Schneider G., Wagner M., Adler G., and Schmid R.M. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123 6 (2002) 2052-2063
9. Grimm C., Wenzel A., Hafezi F., and Remé C.E. Gene expression in the mouse retina: the effect of damaging light. Mol. Vis. 6 (2000) 252-260
10. Hong F., Kim W.H., Tian Z., Jaruga B., Ishac E., Shen X., and Gao B. Elevated interleukin-6 during ethanol consumption acts as a potential endogeneous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-xL proteins. Oncogene 21 1 (2002) 32-43
11. Iizuka N., Hazama S., Yoshimura K., Yoshino S., Tangoku A., Miyamoto K., Okita K., and Oka M. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int. J. Cancer 99 2 (2002) 286-291
12. Kato N., Abe S., Suto M., and Hiraiwa K. Comparison of renal dysfunction in wild-type, IL-6 KO and iNOS KO mice hind limb tourniquet-reperfusion model. Leg. Med. 11 (2009) 248-251
13. Kaushal G.P., Kaushal V., Hong X., and Shah S.V. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 60 5 (2001) 1726-1736
14. Keegan D.J., Kenna P., Humphries M.M., Humphries P., Flitcroft D.I., Coffey P.J., Lund R.D., and Lawrence J.M. Transplantation of syngeneic Schwann cells to the retina of the rhodopsin knockout (rho(-/-)) mouse. Invest. Ophthalmol. Vis. Sci. 44 8 (2003) 3526-3532
15. Kelar M.L., John R., Bennett M., Richardson J.A., Shelton J.M., Chen L., Jeyarajah D.R., Zhou X.J., Zhou H., Chiquett B., Ngami G.T., and Lu C.Y. Maladaptive role of IL-6 in ischemic acute renal failure. J. Am. Soc. Nephrol. 16 11 (2005) 3315-3325
16. Klein C.L., Hoke T.S., Fang W.F., Altmann C.J., Douglas I.S., and Faubel S. Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int. 74 7 (2008) 901-909
17. Lebwohl D., and Canetta R. Clinical development of cisplatin complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer 34 10 (1998) 1522-1534
18. Leibbrandt M.E., Wolfgang G.H., Metz A.L., Ozobia A.A., and Haskins J.R. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 48 3 (1995) 761-770
19. Liu J., Cheng M.L., Shi J.Z., Yang Q., Wu J., Li C.X., and Waalkes M.P. Differential effects between maotai and ethanol on hepatic gene expression in mice: possible role of metallothionein and heme oxygenase-1 induction by maotai. Exp. Biol. Med. 231 9 (2006) 1535-1541
20. Liu K.D., Glidden D.V., Eisner M.D., Parsons P.E., Ware L.B., Wheeler A., Korpak A., Thompson B.T., Chertow G.M., and Matthay M.A. Predictive and pathogenetic values of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit. Care Med. 35 12 (2007) 2866-2867
21. Lu L., Oh D.J., Dursun B., He Z., Hoke T.S., Faubel S., and Edelstein C.L. Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J. Pharmacol. Exp. Ther. 324 1 (2008) 111-117
22. Ma Z., Gong Y., Patel V., Karner C.M., Fischer E., Hiesberger T., Carroll T.J., Pontoglio M., and Igarashi P. Mutations of HNF-1beta inhibit epithelial morphogenesis through dysregulation of SOCS-3. Proc. Natl. Acad. Sci. U.S.A. 104 51 (2007) 20386-20391
23. MacGowan G.A., Mann D.L., Kormos R.L., Feldman A.M., and Murali S. Circulating interleukin-6 in severe heart failure. Am. J. Cardiol. 79 8 (1997) 1128-1131
24. Matsushima H., Yonemura K., Ohishi K., and Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Clin. Med. 131 6 (1998) 518-526
25. Nechemia-Arbely Y., Barkan D., Pizov G., Shriki A., Rose-John S., Galun E., and Axelrod J.H. IL-6/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 19 6 (2008) 1106-1115
26. Overbergh L., Valckx D., Waer M., and Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11 4 (1999) 305-312
27. Ramesh G., and Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 110 6 (2002) 835-842
28. Ramesh G., and Reeves W.B. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int. 65 2 (2004) 490-499
29. Ramesh G., Zhan B., Uematsu S., Akira S., and Reeves W.B. Endotoxicin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. Am. J. Physiol. Renal Physiol. ; 293 1 (2007) F325-F332
30. Rasooly R., Schuster G.U., Gregg J.P., Xiao J.H., Chandraratna R.A., and Stephensen C.B. Retinoid × receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes. J. Immunol. 175 12 (2005) 7916-7929
31. Sekiyama K.D., Yoshiba M., and Thomson A.W. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin. Exp. Immunol. 98 1 (1994) 71-77
32. Simmons E.M., Himmelfarb J., Sezer M.T., Chertow G.M., Mehta R.L., Paganini E.P., Soroko S., Freedman S., Becker K., Spratt D., Shyr Y., and Ikizler T.A. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 65 4 (2004) 1357-1365
33. Sugiyama S., Hayakawa M., Kato T., Hanaki Y., Shimizu K., and Ozawa T. Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidase activity. Biochem. Biophys. Res. Commun. 159 3 (1989) 1121-1127
34. Taga T., and Kishimoto T. gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15 (1997) 797-819
35. Ward N.S., Waxmann A.B., Homer R.J., Mantell L.L., Einarsson O., and Du Y. Interleukin-6-induced protection in heperoxic acute lung injury. Am. J. Respir. Cell Mol. Biol. 22 5 (2000) 535-542
36. Wei Q., Dong G., Franklin J., and Dong Z. The pathological role of bax in cisplatin nephrotoxicity. Kidney Int. 72 1 (2007) 53-62
37. Yan S.F., Tritto I., Pinsky D., Liao H., Huang J., Fuller G., Brett J., May L., and Stern D. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells: central role of the binding site for nuclear factor-IL-6. J. Biol. Chem. 270 19 (1995) 11463-11471